Aptose Biosciences Inc. logo
Aptose Reports Results for the Fourth Quarter and Full Year 2020
March 23, 2021 16:01 ET | Aptose Biosciences, Inc.
- Conference call and webcast at 5pm EDT today - - Company announces resignation of CFO Gregory Chow - - Luxeptinib (CG-806) continues dose escalation and evidence of clinical activity - SAN DIEGO...
Aptose Biosciences Inc. logo
Aptose Expands Senior Leadership Team
March 16, 2021 07:30 ET | Aptose Biosciences, Inc.
George Melko, Pharm.D. joins as Vice President, Regulatory Affairs Robert Killion, Ph.D. appointed Vice President, CMC SAN DIEGO and TORONTO, March 16, 2021 (GLOBE NEWSWIRE) -- Aptose...
Aptose Biosciences Inc. logo
Aptose to Release Fourth Quarter and Year End December 31, 2020 Financial Results and Hold Conference Call on March 23, 2021
March 02, 2021 16:02 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose Presents Highlights from ASH and Corporate Update Event
December 06, 2020 17:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December...
Aptose Biosciences Inc. logo
Aptose to Hold Corporate Update Sunday, December 6th
December 01, 2020 07:30 ET | Aptose Biosciences, Inc.
Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers Poster Presentations for CG-806 and APTO-253 are scheduled for December 5th and 6th at 2020 ASH Annual Meeting...
Aptose Biosciences Inc. logo
Aptose Reports Results for the Third Quarter 2020
November 10, 2020 16:01 ET | Aptose Biosciences, Inc.
Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level Nodal Reductions Observed and Dosing Continues in CG-806 Phase 1 a/b Study in CLL Patients Dosing Continues in...
Aptose Biosciences Inc. logo
Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting
November 04, 2020 10:17 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Biosciences Inc. logo
Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020
October 27, 2020 16:01 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia
October 19, 2020 07:00 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Biosciences Inc. logo
Aptose to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 15, 2020 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...